Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia.
In muscle-invasive bladder cancer, gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) were comparable.
The FDA has approved Copaxone (glatiramer acetate injection) for treatment of patients with relapsing forms of multiple sclerosis.
For men with prostate cancer, clinician referral to and participation in an exercise program has a positive impact on mental health.
Enzalutamide improves health-related quality of life (HRQoL) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
Ibrance (palbociclib) plus fulvestrant met its primary endpoint in progression-free survival for HR+, HER2- metastatic breast cancer
For men with prostate cancer older than 70, prolonged androgen deprivation therapy associated with increased risk of diabetes and cardiovascular disease.
If genetic tests are only done on cancer tissue, as many as half of patients may not receive the most appropriate treatment for their cancer.
Maintenance treatment with capecitabine plus bevacizumab in metastatic colorectal cancer is effective.
Chlorambucil plus ofatumumab is an important treatment option for treatment-naive patients with chronic lymphocytic leukemia (CLL).
Filgrastim may provide a small survival benefit in patients with cancer who are receiving myelosuppressive chemotherapy.
Statin use is inversely associated with pancreatic cancer risk, with evidence of a sex-specific risk reduction.
A novel technology senses small changes in exhaled breath, and identifies changes that signal the development of gastric cancer.
Efficacy of first-line everolimus/bevacizumab and interferon alfa-2a/bevacizumab appears similar in metastatic renal cell carcinoma.
Autologous stem-cell transplantation (ASCT) can be safely performed without transfusion support.
Masitinib plus gemcitabine may be effective in the treatment of specific subgroups of patients with advanced pancreatic ductal adenocarcinoma (PDAC).
Exact Sciences Corp., maker of Cologuard, announced that several insurers are now covering the non-invasive colon cancer at-home test.
Aspirin use does not appear to reduce the risk of mortality associated with prostate cancer.
The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).
Bendamustine plus rituximab safe in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin and mantle cell lymphomas.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Platelet Transfusion for Patients with Cancer
- Autologous Stem Cell Transplantation Safe Without Transfusion Support
- One-Year Trastuzumab with Adjuvant Chemotherapy Provides Benefit
- Quality of Life Outcomes Differ Among Patients with Low-Grade Prostate Cancer
- Myth: Oncology Patients Demand Inappropriate Interventions
- Ibrutinib Active, Safe in Previously Treated Waldenström's Macroglobulinemia
- Neoadjuvant GC with MVAC Have Comparable Efficacy in Bladder Cancer
- Copaxone Approved for Relapsing Multiple Sclerosis
- Internalization: Acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticles
- For Prostate Cancer, Referral-Based Exercise Program Beneficial
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|